Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB4A | P04350 | 2/20 | 0.63 |
| ▸ | TUBB | P07437 | 2/20 | 0.63 |
| ▸ | TUBA3C | P0DPH7 | 2/20 | 0.63 |
| ▸ | TUBA1B | P68363 | 2/20 | 0.63 |
| ▸ | TUBA4A | P68366 | 2/20 | 0.63 |
| ▸ | TUBB4B | P68371 | 2/20 | 0.63 |
| ▸ | TUBB3 | Q13509 | 2/20 | 0.63 |
| ▸ | TUBB2A | Q13885 | 2/20 | 0.63 |
| ▸ | TUBB8 | Q3ZCM7 | 2/20 | 0.63 |
| ▸ | TUBA3E | Q6PEY2 | 2/20 | 0.63 |
| ▸ | TUBA1A | Q71U36 | 2/20 | 0.63 |
| ▸ | TUBA1C | Q9BQE3 | 2/20 | 0.63 |
| ▸ | TUBB6 | Q9BUF5 | 2/20 | 0.63 |
| ▸ | TUBB2B | Q9BVA1 | 2/20 | 0.63 |
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.63 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.61 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.56 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.56 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6490600 | 1.00 | TUBB4A (0.63) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL15882451 | 0.92 | TUBB4A (0.72) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL15882450 | 0.92 | TUBB4A (0.72) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Wr-190433 SCHEMBL29870441 | 0.86 | TUBB4A (0.66) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Wr-190433 SCHEMBL30880222 | 0.86 | TUBB4A (0.66) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Wr-190433 SCHEMBL977482 | 0.86 | TUBB4A (0.66) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Wr-190433 SCHEMBL6180067 | 0.86 | TUBB4A (0.66) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL11473136 | 0.85 | TUBB4A (0.65) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL1604279 | 0.85 | TUBB4A (0.65) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL11473133 | 0.85 | TUBB4A (0.65) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7414048-B2 | 4,5-dihydro-isoxazole derivatives and their pharmaceutical use | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-08-19 | — | — | US | disclosed |
| US-20050038035-A1 | Heterocyclic amide compounds as apolipoprotein b inhibitors | DAISO CO., LTD. (JP) | 2005-02-17 | — | — | US | disclosed |
| EP-1472226-A1 | HETEROCYCLIC AMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-11-03 | — | — | EP | disclosed |
| US-20040058903-A1 | Benzamide compounds as apo b secretion inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-03-25 | — | — | US | disclosed |
| EP-1119568-B1 | 4,5-DIHYDRO-ISOXAZOLE DERIVATIVES AND THEIR PHARMACEUTICAL USE | JANSSEN PHARMACEUTICA NV (BE) | 2004-02-18 | — | — | EP | disclosed |
| US-20040019059-A1 | 4,5-Dihydro-isoxazole derivatives and their pharmaceutical use | FREYNE EDDY JEAN EDGARD (BE) | 2004-01-29 | — | — | US | disclosed |
| EP-1326835-A1 | BENZAMIDE COMPOUNDS AS APO B SECRETION INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-07-16 | — | — | EP | disclosed |
| US-6583141-B1 | T cell mediated rheumatic diseases | JANSSEN PHARMACEUTICA, N.V. (BE) | 2003-06-24 | — | — | US | disclosed |
| WO-2003045921-A1 | HETEROCYCLIC AMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-06-05 | — | — | WO | disclosed |
| WO-2002028835-A1 | BENZAMIDE COMPOUNDS AS APO B SECRETION INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-04-11 | — | — | WO | disclosed |
| EP-1119568-A1 | 4,5-DIHYDRO-ISOXAZOLE DERIVATIVES AND THEIR PHARMACEUTICAL USE | JANSSEN PHARMACEUTICA N.V. (BE) | 2001-08-01 | — | — | EP | disclosed |
| WO-2000021959-A1 | 4,5-DIHYDRO-ISOXAZOLE DERIVATIVES AND THEIR PHARMACEUTICAL USE | JANSSEN PHARMACEUTICA N.V. (BE) | 2000-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040019059-A1 | 4,5-Dihydro-isoxazole derivatives and their pharmaceutical use | CBR1, CYP2D6, HSD3B1 | TUBB4A 2566/4885TUBB 2518/4885TUBA3C 1345/4885 |
| US-20040058903-A1 | Benzamide compounds as apo b secretion inhibitors | APOB, APOL1, SCARB1 | TUBB4A 2807/4885TUBB 2520/4885TUBA3C 4629/4885 |
| US-20050038035-A1 | Heterocyclic amide compounds as apolipoprotein b inhibitors | APOB, APOL1, CTRB2 | TUBB4A 4141/4885TUBB 3440/4885TUBA3C 4616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.